Table 3.
LoVo cells |
HT-29 cells |
||||
Drug exposure | Apoptosis (%) | G0/G1 (%) | Apoptosis (%) | G0/G1 (%) | |
Control | 0 | 74.3 ± 1.3 | 0 | 69.5 ± 1.4 | |
Gefitinib | 1 wk continuous | 10.1 ± 0.5 | 80.4 ± 1.5 | 7 ± 0.4 | 70. 7 ± 1.7 |
2 wk continuous | 23.2 ± 0.9 | 87.9 ± 1.3 | 20 ± 1.2 | 77.2 ± 2.0 | |
1 wk intermittent | 13.8 ± 0.6 | 75.4 ± 1.4 | 6.5 ± 0.3 | 67.1 ± 1.4 | |
2 wk intermittent | 29.7 ± 0.8 | 78.0 ± 2.1 | 18.3 ± 1.8 | 69.7 ± 1.9 | |
Control | 0 | 74.3 ± 2.1 | 0 | 69.5 ± 1.8 | |
ZD6474 | 1 wk continuous | 15.4 ± 0.6 | 77.6 ± 1.9 | 7 ± 0.9 | 71.7 ± 2.1 |
2 wk continuous | 30.3 ± 0.9 | 81.8 ± 2.3 | 15 ± 0.8 | 75.2 ± 2.4 | |
1 wk intermittent | 18.3 ± 1.3 | 74.6 ± 2.1 | 7.3 ± 1.1 | 70.2 ± 1.8 | |
2 wk intermittent | 29.6 ± 1.5 | 76.5 ± 1.5 | 16.4 ± 2.2 | 72.0 ± 1.7 |
Each experiment was conducted in triplicate.